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Email: raffel@umich.eduJ Label Compd Radiopharm. 2019;62:835–842.Fluorine‐18 labeled hydroxyphenethylguanidines were recently developed in
our laboratory as a new class of PET radiopharmaceuticals for quantifying
regional cardiac sympathetic nerve density in heart disease patients. Studies
of 4‐[18F]fluoro‐m‐hydroxyphenethylguanidine ([18F]4F‐MHPG) and 3‐[18F]
fluoro‐p‐hydroxyphenethylguanidine ([18F]3F‐PHPG) in human subjects have
shown that these radiotracers can be used to generate high‐resolution maps
of regional sympathetic nerve density using the Patlak graphical method. Pre-
viously, these compounds were synthesized using iodonium salt precursors,
which provided sufficient radiochemical yields for on‐site clinical PET studies.
However, we were interested in exploring new methods that could offer signif-
icantly higher radiochemical yields. Spirocyclic iodonium ylide precursors have
recently been established as an attractive new approach to radiofluorination of
electron‐rich aromatic compounds, offering several advantages over iodonium
salt precursors. The goal of this study was to prepare a spirocyclic iodonium
ylide precursor for synthesizing [18F]4F‐MHPG and evaluate its efficacy in pro-
duction of this radiopharmaceutical. Under optimized automated reaction con-
ditions, the iodonium ylide precursor provided radiochemical yields averaging
7.8% ± 1.4% (n = 8, EOS, not decay corrected), around threefold higher than
those achieved previously using an iodonium salt precursor. With further opti-
mization and scale‐up, this approach could potentially support commercial dis-
tribution of [18F]4F‐MHPG to PET centers without on‐site radiochemistry
facilities.
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Noninvasive assessment of the extent and severity of
regional cardiac denervation using radiopharmaceuticals
that selectively localize in sympathetic nerve terminals is
an emerging approach to assessing the risk of sudden car-
diac death in patients with heart failure.1 Our laboratorywileyonlinelibrary.comhas recently developed 18F‐labeled hydroxyphenethylgua-
nidines as a new class of radiopharmaceuticals for quanti-
fying regional cardiac sympathetic nerve density using
PET and tracer kinetic analysis. Our studies have focused
on 4‐[18F]fluoro‐m‐hydroxyphenethylguanidine ([18F]4F‐
MHPG) and its structural isomer 3‐[18F]fluoro‐p‐
hydroxyphenethylguanidine ([18F]3F‐PHPG) (Figure 1).© 2019 John Wiley & Sons, Ltd./journal/jlcr 835
FIGURE 1 The structures of [18F]4F‐MHPG and [18F]3F‐PHPG
JUNG ET AL.836These radiotracers exhibit irreversible tissue kinetics
through efficient intraneuronal retention in the norepi-
nephrine storage vesicles localized in cardiac sympathetic
nerve terminals. We previously described the use of
iodonium salt precursors with the guanidine group
completely protected (tetrakis‐Boc) as an effective method
for automated production of [18F]4F‐MHPG and [18F]3F‐
PHPG.2 For example, in production runs of [18F]4F‐MHPG
(n = 15), this approach provided final product yields aver-
aging 1.56 ± 0.68 GBq (range 0.61‐2.84 GBq) at end of syn-
thesis (EOS) with molar activities averaging 58 ± 25 GBq/
μmol (range 21‐105 GBq/μmol), which were adequate for
on‐site clinical studies. Under an exploratory Investiga-
tional New Drug clearance from the US Food and Drug
Administration, we recently conducted first‐in‐human
studies of [18F]4F‐MHPG and [18F]3F‐PHPG in healthy
control subjects.3 Encouraged by the positive results of
these studies, we were interested in evaluating alternative
approaches to the production of [18F]fluoro‐hydroxyphe-
nethylguanidines with the goal of achieving higher radio-
chemical yields for routine clinical production. Among
several new methods developed for radiofluorination of
electron‐rich arenes, spirocyclic iodonium ylides offer sev-
eral advantages, including excellent regioselectivity, high
radiochemical yields, and mild, metal‐free reaction condi-
tions.4-7 In practice, the spirocyclic iodonium ylide
approach is quite similar to our established method using
iodonium salt precursors. The goal of this study was to pre-
pare and evaluate the spirocyclic iodonium ylide analog ofSCHEME 1 The synthesis of the spirocyclic iodonium ylide precurso
SCHEME 2 The two‐step reaction yielding [18F]4F‐MHPG from precthe iodonium salt precursor used previously for [18F]4F‐
MHPG production to test the general utility of iodonium
ylide method for radiofluorination of 18F‐labeled
hydroxyphenethylguanidines. The results demonstrate
that this new approach significantly increases the achiev-
able radiochemical yields of [18F]4F‐MHPG, providing
yet another example of the effectiveness of the use of
spirocyclic ylide precursors for efficient radiofluorination
of electron‐rich aromatic compounds.2 | RESULTS AND DISCUSSION
The synthesis of the required tetrakis‐Boc protected
spirocyclic iodonium ylide precursor 2 is shown in
Scheme 1. Compound 1 (N,N′,N″,N″‐tetrakis (tert‐
butoxycarbonyl)‐N‐3‐benzyloxy‐4‐
iodophenethylguanidine), previously synthesized for our
original approach to [18F]4F‐MHPG,2 was first reacted
with dimethyldioxirane (DMDO). The resulting interme-
diate was coupled with (1r,3r,5r,7r)‐spiro[adamantan‐
2,2′‐[1,3]‐dioxane]‐4′,6′‐dione (SPIAd)5 to give the
spirocyclic iodonium ylide 2.
For initial automated radiofluorination tests with 2, we
employed optimized reaction conditions reported by
Rotstein et al,5 including the use of tetraethylammonium
bicarbonate (TEAB; 4.0 mg) as the fluorine‐18 counter
ion, anhydrous N,N‐dimethylformamide (DMF, 0.5 mL)
as the reaction solvent, 5.0 to 6.0 mg of 2, and reaction
conditions of 120°C for 10 minutes (Scheme 2). The sub-
sequent steps for simultaneous deprotection of the benzyl
ether and the N,N′,N″,N″‐tetrakis‐Boc groups using 3.0 N
HBr followed by HPLC purification of [18F]4F‐MHPG
were identical to those used in our original method.2
Radiochemical yields of these pilot tests (Table 1, Runs
1‐3) were dramatically higher than our original approach,r 2
ursor 2
TABLE 1 Automated tests of [18F]4F‐MHPG production with spirocyclic iodonium ylide precursor 2












1 TEA+ DMF 120 10 >98 8.4 —
2 TEA+ DMF 120 10 >98 9.4 —
3 TEA+ DMF 120 10 >99 9.7 —
4 Cs+ DMF 120 10 — — —
5 K+/K222 DMF 120 10 >89 0.3 —
6 K+/K222 DMF 120 10 >96 1.1 —
7 TEA+ MeCN 120 10 >75 0.4 —
8 TEA+ MeCN 120 10 >95 1.0 —
9 TEA+ DMF 150 3 >99 3.8 —
10 TEA+ DMF 120 5 >96 6.2 —
11 TEA+ DMF 120 10 >98 8.3 —
QC1 TEA+ DMF 120 10 >99 6.9 130.5
QC2 TEA+ DMF 120 10 >99 5.8 105.8
QC3 TEA+ DMF 120 10 >99 6.7 137.9
QC4 TEA+ DMF 120 10 >99 7.0 >225
Note. Reactions were performed in 0.5 mL of solvent using 5.0 to 6.6‐mg precursor and 3.5 to 5.4 mg of fluoride counter ion. Symbol “—“denotes that the value
was not determined. K222 = Kryptofix 222.
JUNG ET AL. 837averaging 9.2% ± 0.7% (range 8.4%‐9.7%) at EOS (not
decay corrected), more than threefold higher than the
average yield of [18F]4F‐MHPG achieved with our
iodonium salt precursor approach.2
Encouraged by these trial studies, we sought to opti-
mize reaction conditions through a series of manual reac-
tion tests. First, we tested the effect of using different
fluorine‐18 counter ions, including TEA+, K+/Kryptofix
222, and Cs+. The results showed that TEA+ was the clear
choice, as K+/Kryptofix 222 and Cs+ yielded only trace
quantities of radiolabeled intermediate (data not shown).
Next, we tested acetonitrile as the reaction solvent, based
on a report suggesting it might provide better yields,8 but
again, low yields of product were obtained (data not
shown). Finally, reaction temperatures and times were
optimized using TEA+ as the fluoride counter ion and
DMF as the solvent. The effects of reaction temperature
and reaction time using 4 mg of TEAB in 0.5 mL of
DMF solvent are shown in Figure 2A. The best yields
were obtained at 120°C for reaction times between 3
and 10 minutes. Tests of three different concentrations
of the fluoride counter ion showed that 4 mg of TEAB
per 0.5 mL of DMF solvent gave the highest yields at a
reaction temperature of 120°C and reaction times of 5 to
10 minutes (Figure 2B). The general trend of decreasing
radiochemical yields with longer‐reaction times is likely
due to a combination of thermal decomposition of the
spirocyclic iodonium ylide 2 and the radiolabeledintermediate [18F]3. For example, melting point tests of
2 showed a broad melting point around 80°C to 89°C,
followed by generation of bubbles in the open capillary
tube at temperatures between 110°C and 120°C. We
hypothesize that the bubbles were caused by generation
of CO2 during thermolysis of the N,N′,N′′,N′′‐tetrakis‐
Boc groups between 110°C and 120°C.9,10
The findings of the initial automated tests (Table 1,
Runs 1‐3) and the manual reaction tests were confirmed
in some additional automated production runs of
[18F]4F‐MHPG. Automated syntheses using Cs+ and K
+/Kryptofix 222 as fluoride counter ions in DMF solvent
were again found to provide extremely low yields
(Table 1, Runs 4‐6). Similarly, yields were very low
using TEA+ as the fluoride counter ion in MeCN sol-
vent (Table 1, Runs 7‐8). Using TEA+ in DMF, a short
reaction time of 3 minutes at high temperature
(150°C) gave a moderate yield of 3.8% (Table 1, Run
9), while a higher yield of 6.2% was achieved for a 5‐
minute reaction time at 120°C (Table 1, Run 10).
Finally, a few runs were performed using optimized
conditions (TEA+ in DMF for 10 min at 120°C), and
the final products were analyzed with the series of qual-
ity control (QC) tests currently used at our institution
for clinical PET studies with this radiopharmaceutical
(Table 1, Runs QC1‐QC4). The time from end‐of‐beam
to formulation was 90 to 95 minutes, including HPLC
purification. An example of the HPLC data acquired
(A)
(B)
FIGURE 2 Radiochemical yields of the radiolabeled
intermediate [18F]3 as a function of reaction time for (A) different




FIGURE 3 HPLC purification of [18F]4F‐MHPG; (A) radiation
detector chromatogram, showing collection of [18F]4F‐MHPG
from 27 to 32 minutes and (B) the corresponding UV detector data
at λ = 220 nm
JUNG ET AL.838during purification and collection of [18F]4F‐MHPG is
shown in Figure 3. Good radiochemical yields were
achieved (5.8%‐8.3%), consistent with the findings of
the manual reaction tests. Radiochemical purities were
high (>99%), and molar activities ranged from 105.8 to
greater than 225 GBq/mmol (Table 1). All other QC
tests (mass concentration, radiochemical identity,
radionuclidic identity, pH, visual inspection for particu-
lates and color, residual solvents tests, ethanol content,
filter membrane integrity, and sterility) were passed by
each batch of [18F]4F‐MHPG. Representative data of
an HPLC study to confirm radiochemical identity
of the product are shown in Figure 4. Together, these
results demonstrate the ability of the spirocyclic
iodonium ylide method to reliably produce [18F]4F‐
MHPG for clinical PET studies.
While the United States Pharmacopeia (USP) does not
cite a release limit for tetraethylammonium ion (TEA+),Institutional Review Boards may require QC testing of
TEA+ concentrations in the final [18F]4F‐MHPG formula-
tion. For example, the European Pharmacopeia sets a
release limit for the closely related tetrabutylammonium
ion (TBA+) of 2.6 mg/V (per patient dose), and QC tests
have been developed to evaluate TBA+ levels in PET
radiopharmaceutical products.11 Since our optimized
iodonium ylide approach to [18F]4F‐MHPG uses 4.0 mg
of TEA+, and the compound is purified using HPLC, it
is unlikely that residual TEA+ levels would preclude use
of the final product in human subjects. Supporting this,
a recent report on an improved synthesis of [18F]
fluorodopamine for human studies (which uses HPLC
purification of the final product) described a QC testing
method for TEA+ concentrations, which averaged
around 50 μg/mL when starting with up to 3.5 mg of
tetraethylammonium bicarbonate per reaction.12
The radiochemical yields of [18F]4F‐MHPG achieved
with the spirocyclic iodonium ylide 2 under optimized
reaction conditions averaged 7.8% ± 1.4% (n = 8, range
5.8%‐9.7%, Table 1). In comparison, these are lower
than the reported yield of 14% achieved with a closely
related spirocyclic iodonium ylide precursor to prepare
meta‐[18F]fluoro‐benzylguanidine ([18F]mFBG).5 This is
not surprising, as the protected m‐hydroxyl group in pre-
cursor 2 is electron‐rich, which would be expected to
cause lower radiochemical yields for our compound. Nev-
ertheless, the higher and more consistent radiochemical
yields of [18F]4F‐MHPG achieved using 2 compared with
our earlier results using an iodonium salt precursor repre-
sents a noteworthy improvement in the production of this
radiopharmaceutical for clinical use.
FIGURE 4 Coinjection study to confirm radiochemical identity.
An aliquot of [18F]4F‐MHPG product was spiked with cold
standard [19F]4F‐MHPG and analyzed using HPLC. The relative
retention times of the peaks in the UV chromatogram (Rt = 9.1 min)
and the radiation detector chromatogram (Rt = 9.8 min) is
consistent with an established delay time of 0.7 minutes between
the UV and radiation detectors. A small amount of free [18F]F– (~2%
of the total activity) appears at Rt = 5.4 minutes in the radiation
detector trace. HPLC conditions: Synergi 10 μ Hydro‐RP column,
4.6 × 250 mm, 60mM sodium phosphate buffer, pH 5.4 with 10%
ethanol, flow rate 1.0 mL/min, UV absorbance at 220 nm
JUNG ET AL. 8393 | CONCLUSIONS
The use of a spirocyclic iodonium ylide precursor for
automated production of the cardiac sympathetic inner-
vation radiotracer [18F]4F‐MHPG was evaluated and
found to consistently provide higher radiochemical yields
than the previous approach using an iodonium salt pre-
cursor. This improved method of [18F]4F‐MHPG produc-
tion is well suited to on‐site production for clinical PET
studies and could possibly be scaled up for distribution
of the radiotracer to stand‐alone PET centers without a
cyclotron and radiochemistry facility.4 | EXPERIMENTAL
4.1 | General
Reagents and solvents were purchased from commercial
sources and used without further purification unlessotherwise noted. N,N′,N″,N″‐tetrakis (tert‐butoxycar-
bonyl)‐N‐3‐benzyloxy‐4‐iodophenethylguanidine 1, N,N′,
N″,N″‐tetrakis (tert‐butoxycarbonyl)‐N‐3‐benzyloxy‐4‐fluo
-rophenethylguanidine 3, and 4‐fluoro‐m‐hydroxyphene-
thylguanidine (4F‐MHPG) were previously prepared in
our laboratory.2,13,14 Compound 1 was used to synthesize
the spirocyclic iodonium ylide precursor 2. Compound 3
and 4F‐MHPG were used as reference standards for
radio‐HPLC and radio‐TLC analysis. DMDO15 and (1r,
3r,5r,7r)‐spiro[adamantan‐2,2′‐[1,3]‐dioxane]‐4′,6′‐dione
(SPIAd)5 were prepared using previously reported
methods.
NMR spectra were obtained on a Varian vnmrs 500
(500.10 MHz for 1H; 125.70 MHz for 13C) spectrometer.
1H and 13C NMR chemical shifts (δ) are reported in parts
per million (ppm) relative to internal standard TMS, and
coupling constants (J) are in Hz. High‐resolution mass
spectra were obtained on a VG (Micromass) 70‐250S spec-
trometer using electrospray ionization (ESI) in positive
ion mode at 70 eV. Flash column chromatography was





A solution of DMDO in acetone was added dropwise to a
cooled (0°C) solution of N,N′,N″,N″‐tetrakis (tert‐
butoxycarbonyl)‐N‐3‐benzyloxy‐4‐
iodophenethylguanidine 1 (200 mg, 0.25 mmol) in ace-
tone and acetic acid (4:1, 2.5 mL) until the starting guani-
dine compound 1 had disappeared, as assessed by TLC
analysis. The mixture was stirred at 0°C for 1 hour and
then warmed to room temperature. It was then concen-
trated under reduced pressure. The residue was diluted
with ethanol (5 mL) and treated by addition of
(1r,3r,5r,7r)‐spiro[adamantan‐2,2′‐[1,3]‐dioxane]‐4′,6′‐
dione (SPIAd, 70 mg) in portions. The resulting solution
was adjusted to pH 10 by addition of a 10% aqueous
Na2CO3 solution, stirred for 2 hours at room temperature,
diluted with water (10 mL), and then extracted with ethyl
acetate (3 × 50 mL). The combined extracts were washed
with brine, dried over anhydrous Na2SO4, and concen-
trated under reduced pressure. The residue was purified
by flash column chromatography (silica gel, 30%‐40%
ethyl acetate in hexane) to afford the product 2 (179 mg,
69%) as a white solid; 1H NMR (500 MHz, CDCl3) δ
7.44‐7.39 (m, 5H), 7.25 (d, J = 7.9 Hz, 1H), 7.04 (s, 1H),
6.99 (d, J = 7.9 Hz, 1H), 5.21 (s, 2H), 3.94 (t, J = 8.0 Hz,
JUNG ET AL.8402H), 2.98 (t, J = 8.0 Hz, 2H), 2.52 (br. s, 2H), 2.22 (br. s,
2H), 2.20 (br. s, 2H), 1.88 (br. s, 2H), 1.74 (br. s, 4H),
1.72 (br. s, 2H), 1.52‐1.47(m, 36H); 13C NMR (125 MHz,
CDCl3) δ 163.80, 157.98, 154.82, 151.38, 147.80, 145.06,
144.12, 135.10, 129.26, 129.21, 129.14, 128.32, 125.59,
114.86, 107.90, 100.19, 84.32, 84.17, 82.53, 72.44, 48.79,
37.53, 36.95, 35.96, 34.08, 33.46, 28.34, 28.27, 28.25,
26.88; HRMS (ESI+) m/z calculated for C49H64IN3O13
[M + Na]+: 1052.3376, found 1052.3373.4.3 | Radiochemistry
4.3.1 | General
Ethanol (200 proof, USP) was purchased from Decon Lab-
oratories, Inc. USP grade sodium chloride 0.9%, and sterile
water for injection, were sourced from Hospira. Millex GV
(#SLGV013SL) and FG (#SLFG025LS) filters were pur-
chased from Millipore. Sep‐Pak Light QMA cartridges
(#WAT023525) were purchased fromWaters Corporation.
Light QMA cartridges were conditioned with sequential
flushes of 10 mL of ethanol, followed by 10 mL of sterile
water, 10 mL of 0.5 M NaHCO3 preconditioning solution,
and finally 10 mL of sterile water prior to use.
Using a GE Healthcare PETrace 880 cyclotron, a target
containing water enriched with 18O was irradiated with
16 MeV protons to yield [18F]fluoride ([18F]F–) via the
18O(p,n)18F reaction. [18F]F– was isolated from the
enriched water by trapping on a preconditioned Sep‐Pak
Light QMA cartridge. The [18F]fluoride was then used
in manual reaction tests or for automated radiosyntheses
of [18F]4F‐MHPG using a TRACERLab FXFN synthesis
module. Radiochemical reactions were analyzed by
radio‐TLC or HPLC. For manual tests, radio‐TLC analysis
was performed using a Bioscan AR 2000 Radio‐TLC scan-
ner with EMD Millipore TLC silica gel 60 plates (3.0 × 6.5
cm). For the automated syntheses, the radiochemical
purity of [18F]4F‐MHPG was measured using a Shimadzu
LC‐2010A HT system equipped with a Bioscan B‐FC‐1000
radiation detector under isocratic conditions (Jupiter C18
5 μ column, 4.6 × 250 mm, 60mM NaHPO4 buffer, pH
5.4, with 10% ethanol, flow rate 1.1 mL/min, λ = 254
nm, 40°C oven). A few batches of [18F]4F‐MHPG pre-
pared under optimized automated reaction conditions
were tested using the full QC protocol developed for
human PET studies, including molar activity determina-
tion and residual solvents analyses.4.3.2 | Manual reactions
Tetraethylammonium [18F]fluoride (Et4N[
18F]F) was pre-
pared using a TRACERLab FXFN synthesis module(General Electric, GE). [18F]F– was produced using a
short beam time on the GE PETrace cyclotron (55 μA
beam for 30‐45 s) and trapped on a preconditioned Sep‐
Pak Light QMA cartridge. The trapped [18F]F– was
eluted into the reaction vessel with a mixture of
tetraethylammonium bicarbonate (Et4NHCO3, 4.0 mg),
H2O (0.3 mL), and MeCN (0.7 mL). After additional
MeCN (0.5 mL) was added to the reaction vessel, the
resulting solution was azeotropically dried under vacuum
at 90°C for 4 minutes, followed by a nitrogen stream and
simultaneous vacuum draw at 70°C for an additional 4
minutes. Anhydrous N,N‐dimethylformamide (6 mL)
was added into the reaction vessel, and the resulting solu-
tion was transferred to a sterile vial to provide approxi-
mately 1.5 GBq of anhydrous Et4N[
18F]F for manual
radiolabeling tests.
Manual reaction tests for optimizing radiolabeling
conditions using the spirocyclic iodonium ylide precursor
2 were carried out using different reaction temperatures,
reaction times, and tetraethylammonium bicarbonate
concentrations. For most tests, a stock solution of
Et4NHCO3 was prepared (72.0 mg of dried Et4NHCO3
in 9.0 mL of anhydrous DMF, 41.8 mM), and aliquots of
this solution were used for manual reactions. A 0.5‐mL
aliquot of the Et4NHCO3 stock solution was added to a
4‐mL amber glass vial containing precursor 2 (~4.0 mg,
3.8 μmol). The reaction vial was sealed with a
PTFE/Silicone septum cap and the solution thoroughly
mixed. Using a 100‐μL glass syringe, a 50‐μL aliquot of
Et4N[
18F]F (7.5‐15.0 MBq, prepared as described above)
was added to the reaction vial. The vial was then heated
in an aluminum block at one of four temperatures (105,
120, 135, or 150°C). After reaction times of 3, 5, 10, 15,
or 20 minutes, a 10‐μL aliquot of the reaction mixture
was withdrawn from the reaction vial and analyzed by
radio‐TLC (EtOAc/hexane, 1:3, v/v) to determine the
radiochemical yield (%) of the radiofluorinated
intermediate [18F]3 (see Scheme 2). Another series of
tests evaluated the effect of different amounts of
tetraethylammonium bicarbonate on radiochemical
yields. Using a constant temperature of 120°C, the radio-
chemical yields of [18F]3 achieved with 2.0, 4.0, and 6.0
mg of Et4NHCO3 dissolved in the 0.5 mL of DMF added
to the reaction vial were measured at reaction times of
5, 10, 15, and 20 minutes.4.3.3 | Automated synthesis
Our manual and automated reaction tests with the
spirocyclic iodonium ylide precursor led to the
following improved automated synthesis of [18F]4F‐
MHPG (Scheme 2). For a 30‐minute target irradiation
JUNG ET AL. 841at 55‐μA beam current, approximately 65 GBq of [18F]F
− was produced and trapped on the preconditioned Sep‐
Pak Light QMA cartridge. [18F]F− was eluted from the
cartridge into the reactor vessel of the TRACERlab
FXFN system with a solution of Et4NHCO3 (~4 mg in
0.4 mL of H2O and 1.0 mL of MeCN). The
water/acetonitrile mixture was evaporated under vac-
uum at 90°C for 4 minutes, followed by a nitrogen
stream and simultaneous vacuum draw at 70°C for an
additional 4 minutes to yield dried Et4N[
18F]F. After
cooling to 60°C, a mixed solution of 0.5 mL of DMF
containing 5.5 to 6.0 mg of the spirocyclic iodonium
ylide precursor 2 was added to the reactor vessel con-
taining Et4N[
18F]F. The mixture was heated in the
sealed reactor vessel at 120°C for 10 minutes to produce
3‐benzyloxy‐4‐[18F]fluorophenethyl‐N,N′,N″,N″‐tetrakis‐
BOC‐guanidine [18F]3 as intermediate. After cooling to
70°C, a solution of 48% HBr (0.5 mL) and MeCN (0.5
mL) was added to the reaction mixture. The solution
was heated at 120°C for 15 minutes and then cooled
to 50°C. Next, a mixture of aqueous NaOH (1.0 mL,
4.0 M in H2O) and buffer solution (1.5 mL, 5% EtOH
in 40 mM NH4OAc) was added into the reactor vessel.
This mixture was injected onto a reverse phase HPLC
column (Phenomenex Synergi 10 μm Hydro‐RP 80 Å,
250 × 10 mm, 5% EtOH in 40 mM NH4OAc buffer, flow
rate 4.0 mL/min, λ = 220 nm), and [18F]4F‐MHPG was
collected at Rt = 27 to 32 minutes. The collected frac-
tion was passed through a 0.22‐μm sterilizing filter
directly into a septum‐sealed, sterile, pyrogen‐free glass
vial. An aliquot of the filtered product was analyzed
with HPLC to confirm the radiochemical identity as
[18F]4F‐MHPG.4.3.4 | QC testing
Molar activity was determined by analyzing an aliquot of
[18F]4F‐MHPG with known activity A0 (kBq) using a
reverse‐phase HPLC system with radiodetection. The area
under the UV absorbance peak associated with the
[18F]4F‐MHPG radioactivity peak was compared with a
calibration curve to estimate the total mass of 4F‐MHPG
(μg) in the aliquot. The ratio of sample activity (A0) to
the measured total mass (converted from μg to μmol)
gave the molar activity of the sample. Radiochemical
purity of the product was measured as the fractional area
under [18F]4F‐MHPG peak in the baseline‐subtracted
curve measured by the radiodetector. Additional QC tests
included radiochemical identity, radionuclidic identity,
radionuclidic purity, pH, visual inspection for particulates
and color, bacterial endotoxin test, and residual solvents
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